RIEMSER Pharma GmbH
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From RIEMSER Pharma GmbH
Stada and Mabxience have received an endorsement from the EMA for their partnered bevacizumab biosimilar rival to Avastin. Meanwhile, Riemser’s thiotepa generic and two Teva inhalers have also received positive opinions from the CHMP.
New products from Paion, Arvelle, Incyte and many others have been recommended for approval by the European Medicines Agency. Meanwhile, the agency has explained why the EU marketing authorization application for Dexamethasone Taw, for treating COVID-19 patients, was withdrawn.
The JP Morgan conference uptick in biopharma deal-making has begun with more than 20 deals announced this week, including the latest Bayer/Evotec partnership and Pfizer’s cancer tie-up with eFFECTOR.
Q3 2012 biopharma financing, at just over $3 billion, showed a 13% increase over Q2. Follow-on public offerings again were the most prevalent financing type, accounting for a third of these dollars. M&A volume was down to just over $7 billion, compared with Q2’s $35.9 billion and only two Q3 transactions topped the billion-dollar mark. Antibody alliances made up just over a quarter of the total $2.2 billion in deal volume, with 19 deals signed in the area.
- Specialty Pharmaceuticals
- Implantable Devices
- Other Names / Subsidiaries
- Riemser Arzneimittel AG
- RIEMSER Iberia s.l.
- Esteve Healthcare